The European Commission announced this week its approval of Sanofi’s (NASDAQ: SNY) Sarclisa (isatuximab) subcutaneous (SC) formulation in combination with standard treatment regimens for multiple myeloma (MM), covering all current indications previously approved for the intravenous (IV) formulation.
Contents
Regulatory Milestone
| Component | Detail |
|---|---|
| Drug Name | Sarclisa (isatuximab) subcutaneous formulation |
| Developer | Sanofi (NASDAQ: SNY) |
| Regulatory Authority | European Commission |
| Approval Scope | All existing IV formulation indications for multiple myeloma |
| Basis for Approval | Phase III IRAKLIA study (NCT05405166) |
| Key Finding | Non-inferiority of SC vs. IV formulation |
Approved Indications – Multiple Myeloma
Newly Diagnosed Multiple Myeloma
- Transplant-Ineligible Patients: In combination with bortezomib, lenalidomide, and dexamethasone (VRd)
- Transplant-Eligible Patients: In combination with bortezomib, lenalidomide, and dexamethasone (VRd)
Relapsed/Refractory Multiple Myeloma
- Pomalidomide-Based Regimen: In combination with pomalidomide and dexamethasone (Pd)
- Carfilzomib-Based Regimen: In combination with carfilzomib and dexamethasone (Kd)
Clinical Trial Results – IRAKLIA Study
| Parameter | Outcome |
|---|---|
| Study Design | Pivotal Phase III, randomized, non-inferiority |
| Primary Endpoint | Pharmacokinetic and efficacy non-inferiority of SC vs. IV |
| Trial Identifier | NCT05405166 |
| Key Result | Subcutaneous formulation demonstrated non-inferiority to intravenous formulation |
| Patient Benefit | Reduced administration time and improved convenience |
Strategic Implications
- Administration Advantage: Subcutaneous delivery offers significantly shorter administration time compared to IV infusion
- Patient Experience: Enhanced convenience and reduced clinic time for patients requiring chronic therapy
- Healthcare Efficiency: Reduced burden on infusion centers and nursing resources
- Commercial Expansion: Potential to increase market share through improved patient and provider preference
Market Context
- Multiple Myeloma Prevalence: Approximately 50,000 new cases annually in Europe
- Anti-CD38 Competition: Competitive landscape includes daratumumab (Darzalex) and other CD38-targeting agents
- Subcutaneous Trend: Growing preference for SC formulations across oncology therapeutic classes
- Treatment Duration: Multiple myeloma requires long-term therapy, making administration convenience a key differentiator
Forward-Looking Statements
This brief contains forward-looking statements regarding regulatory approvals, market opportunities, and commercial expectations. Actual results may differ due to risks including market adoption, competitive dynamics, reimbursement challenges, and post-marketing safety surveillance requirements.-Fineline Info & Tech
